Glenmark receives ANDA approval for Linezolid Tablets
22 December 2015 | News | By BioSpectrum Bureau
Glenmark receives ANDA approval for Linezolid Tablets
The drug is therapeutic equivalent of Zyvox Tablets
Glenmark Pharmaceuticals (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Linezolid Tablets, 600 mg.
The drug is therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer.
According to IMS Health sales data for the 12 month period ending October 2015, the Zyvox Tablets, 600 mg market achieved annual sales of approximately $447.6
million.
